SAN DIEGO, Sept. 3, 2015 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX) announced today that it has
appointed Alfred W. Sandrock, Jr.,
M.D., Ph.D. to its Board of Directors effective immediately. Dr.
Sandrock is the current Group Senior Vice President and Chief
Medical Officer of Biogen Inc. (NASDAQ: BIIB).
"We are fortunate to have a person of Al's caliber join our
Board of Directors. Dr. Sandrock brings a distinguished track
record of success in the development, approval and
commercialization of many significant neurological products
including Tysabri® and Tecfidera®," said William H. Rastetter, Chairman of the Board of
Neurocrine Biosciences. "His knowledge and expertise will be a
valuable resource for Neurocrine's continued transition into a
commercial organization."
Since May 2013, Dr. Sandrock has
served as the Group Senior Vice President and Chief Medical Officer
of Biogen Inc., a publicly traded global biotechnology company.
From February 2012 to April 2013 he served as Senior Vice President/
Chief Medical Officer of Biogen, and since joining Biogen in 1998,
has held several senior executive positions, including Senior Vice
President of Development Sciences, Senior Vice President of
Neurology Research and Development, and Vice President of Clinical
Development, Neurology. During his tenure at Biogen, Dr. Sandrock
has been responsible for the clinical development and approval of
Tysabri®, Plegridy®, Tecfidera®, Alprolix®, and Eloctate®.
Dr. Sandrock received his B.A. in human biology from
Stanford University, an M.D. from
Harvard Medical School and a Ph.D. in
neurobiology from Harvard University.
Dr. Sandrock completed an internship in medicine, a residency and
chief residency in neurology, and a clinical fellowship in
Neuromuscular Disease and Clinical Neurophysiology
(electromyography) at Massachusetts General Hospital.
Neurocrine Biosciences, Inc. discovers and develops innovative
and life-changing pharmaceuticals, in diseases with high unmet
medical needs, through its novel R&D platform, focused on
neurological and endocrine based diseases and disorders. The
Company's two lead late-stage clinical programs are elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc., and NBI-98854, a vesicular monoamine
transporter 2 inhibitor for the treatment of movement
disorders. Neurocrine intends to maintain certain commercial
rights to its VMAT2 inhibitor for evolution into a fully-integrated
pharmaceutical company.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-the-appointment-of-dr-alfred-w-sandrock-to-its-board-of-directors-300135612.html
SOURCE Neurocrine Biosciences, Inc.